Sam is a strategic advisor with over 7 years of experience in the life sciences industry, specializing in commercial strategy. His background spans management consulting, investor relations, marketing, and biotech incubation—providing a well-rounded perspective on the challenges biopharma companies face across the product lifecycle.
Sam has worked across a range of therapeutic areas including neuroscience, rare disease, hematology/oncology, and immunology. His project experience includes launch and brand strategy, portfolio and pipeline planning, market access, and early opportunity assessments. He has supported both emerging biotech and large pharma clients in aligning internal teams, navigating complex stakeholder dynamics, and preparing for successful product launches.
Prior to joining Asymmetry Group, Sam was a management consultant in Oliver Wyman’s Health and Life Sciences practice, where he led and supported projects spanning corporate strategy, product positioning, portfolio planning, and competitive intelligence. Earlier in his career, he worked in investor relations, advising public and private biotech companies on communicating their science and strategy to institutional investors and analysts, and at a pharmaceutical marketing agency, where he supported several blockbuster launches.
Sam holds an M.B.A. from Duke University’s Fuqua School of Business and a B.S. in Neuroscience from Binghamton University.